Trial Outcomes & Findings for Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo (NCT NCT00564265)

Results Overview

The outcomes were measured through follow-up visits of the patients to the out-patient clinic of our institution at 15 days, 1 month, 3 months, 6 months, 1 year, and after that, every year after the surgical treatment.

Recruitment status

COMPLETED

Target enrollment

24 participants

Primary outcome timeframe

5 years

Results posted on

2011-08-11

Participant Flow

Hospital patients operated on for Gastrointestinal stromal tumor (GIST)

The intention was to include all consecutive patients with GIST who presented during the study period. All consecutive patients with GIST were included during the study period

Participant milestones

Participant milestones
Measure	Gastrointestinal Stromal Tumor (GIST) GIST in all locations: Stomach, duodenum, jejunum, ileum, and rectum. All patients were submitted to surgery and in 2 cases are on Imatinib therapy.
Overall Study STARTED	24
Overall Study COMPLETED	24
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Gastrointestinal Stromal Tumor (GIST) n=24 Participants GIST in all locations: Stomach, duodenum, jejunum, ileum, and rectum. All patients were submitted to surgery and in 2 cases are on Imatinib therapy.
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	22 Participants n=5 Participants
Age, Categorical >=65 years	2 Participants n=5 Participants
Age Continuous	49 years STANDARD_DEVIATION 15.4 • n=5 Participants
Sex: Female, Male Female	12 Participants n=5 Participants
Sex: Female, Male Male	12 Participants n=5 Participants
Region of Enrollment Chile	24 participants n=5 Participants

PRIMARY outcome

Timeframe: 5 years

Population: This is a consecutive sample of all patients operated on for GISTs in 3 hospitals during a period of 5 years. The period of 5 years was determined by the time that we count with inmunochemistry to confirm GISTs at our institutions, and that time would be the last 5 years. The Last Observation Carried Dorward (LOCF) was made in August 2008.

The outcomes were measured through follow-up visits of the patients to the out-patient clinic of our institution at 15 days, 1 month, 3 months, 6 months, 1 year, and after that, every year after the surgical treatment.

Outcome measures

Outcome measures
Measure	Gastrointestinal Stromal Tumor (GIST) n=24 Participants GIST in all locations: Stomach, duodenum, jejunum, ileum, and rectum. All patients were submitted to surgery and in 2 cases are on Imatinib therapy.
Number of Patients Who Survived	5 Participants

Adverse Events

Gastrointestinal Stromal Tumor (GIST)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Marcelo A. Beltran

Hospital de La Serena

Phone: 56 - 51 - 485923

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place